Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > comgrats

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Nov 18, 2023 10:13am

234 Views

Post# 35742506

RE:RE:comgrats

I hope you are just kidding WalkOverTheStrt.

That question will never lead to understanding the drug, the true value of the drug or where P2 and P3 are going.

I know that many use that as a barometer of where any company is going - but - we are way past that discussion.

It's going to be about the following ...
- Nuance resolution
- P2 planning
- Chronic path
- new molecules
- breakthrough therapy designation
- partnnering opportunities

And ... take nothing for granted. Nothing is ever easy. Drug development is difficult business.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario